Company

Excellamol is a biomedical company developing therapeutics derived from naturally occurring extracellular matrix components to enable targeted delivery of highly potent anticancer agents. Supported by extensive mechanistic studies in cellular and animal models, along with a strong proprietary patent portfolio, Excellamol has established the Self-Depot™ OncoPDC platform for the development of novel, first-in-class polypeptide-drug conjugate therapeutics for cancer treatment.